Product Code: GVR-4-68040-411-3
Pulsed Field Ablation Market Size & Trends:
The global pulsed field ablation market size was estimated at USD 116.6 million in 2023 and is projected to grow at a CAGR of 37.7% from 2024 to 2030. This is driven by its promise as a safer and more effective alternative to traditional thermal ablation methods. As the global prevalence of atrial fibrillation (AF) rises, there is an increasing demand for innovative treatment options that offer fewer complications and improved outcomes. PFA's non-thermal mechanism significantly reduces the risk of damaging surrounding tissues, a major limitation of conventional ablation techniques like radiofrequency and cryoablation. This unique advantage has led to growing interest from healthcare providers and patients, accelerating its adoption in clinical settings.
Cardiac arrhythmias, particularly atrial fibrillation (AF), are increasingly prevalent, affecting millions worldwide. AF, characterized by an irregular and often rapid heart rate, is the most common type of sustained arrhythmia, significantly raising the risk of stroke, heart failure, and other serious cardiovascular complications. As global populations age and the incidence of lifestyle-related risk factors, such as hypertension and obesity, rises, the number of AF cases continues to grow.
According to the Johnson & Johnson Services, Inc. article published in February 2024, more than 37.5 million people globally live with this condition, emphasizing its widespread impact. The risk of developing AFib is notably high; statistics reveal that about one in four adults over the age of 40 experience this arrhythmia at some point in their lives. This growing prevalence highlights the urgent need for effective management and prevention strategies.
This escalating burden has created a substantial demand for effective, minimally invasive treatment options. Traditional therapies like antiarrhythmic drugs and catheter-based ablation have limitations, leading to an unmet need for safer, more efficient approaches. The increasing prevalence of arrhythmias is thus a key driver of market growth for advanced treatment technologies like pulsed field ablation (PFA), which offer improved safety profiles and efficacy compared to conventional methods.
Moreover, technological advancements are a key driver of the PFA market's growth, as ongoing innovations enhance ablation procedures precision, safety, and efficacy. Leading medical device companies are investing heavily in the development of next-generation PFA systems, focusing on improving energy delivery, catheter design, and procedural efficiency. For instance, innovations in catheter flexibility and the integration of real-time imaging and mapping technologies allow for more targeted and controlled ablation, reducing the risk of complications and improving patient outcomes. Additionally, the development of multipolar PFA catheters that can treat larger areas in a single application is further expanding the potential applications of this technology, making it a versatile tool in the electrophysiology arsenal.
Furthermore, regulatory approvals are critical in influencing the PFA market, as they validate the safety and efficacy of these novel devices, paving the way for broader clinical adoption. In recent years, several PFA systems have received CE marking in Europe, allowing them to be marketed and used across the continent. These approvals are often based on positive clinical trial results that demonstrate the benefits of PFA over traditional methods, particularly in terms of reduced procedure times and fewer complications.
Global Pulsed Field Ablation Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global pulsed field ablation market report based on the components, indication, end-use, and region.
- Components Outlook (Revenue, USD Million, 2018 - 2030)
- Catheters
- Generators
- Indication Outlook (Revenue, USD Million, 2018 - 2030)
- Atrial Fibrillation
- Non-atrial Fibrillation
- End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Inpatient Facilities
- Outpatient Facilities
- Regional Outlook (Revenue, USD Million; 2018 - 2030)
- North America
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Norway
- Denmark
- Sweden
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Segment Definitions
- 1.2.1. Components
- 1.2.2. Indication
- 1.2.3. End use
- 1.2.4. Regional Scope
- 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Components outlook
- 2.2.2. Indication outlook
- 2.2.3. End use outlook
- 2.3. Regional outlook
- 2.4. Competitive Insights
Chapter 3. Pulsed Field Ablation Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Pulsed Field Ablation Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Bargaining power of suppliers
- 3.3.1.2. Bargaining power of buyers
- 3.3.1.3. Threat of substitutes
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic landscape
- 3.3.2.3. Social landscape
- 3.3.2.4. Technological landscape
- 3.3.2.5. Environmental landscape
- 3.3.2.6. Legal landscape
Chapter 4. Pulsed Field Ablation Market: Components Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Pulsed Field Ablation Market: Components Movement Analysis
- 4.3. Pulsed Field Ablation Market by Components Outlook (USD Million)
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.5. Catheters
- 4.5.1. Catheters Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.6. Generators
- 4.6.1. Generators Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Pulsed Field Ablation Market: Indication Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Pulsed Field Ablation Market: Indication Movement Analysis
- 5.3. Pulsed Field Ablation Market by Indication Outlook (USD Million)
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.5. Atrial Fibrillation
- 5.5.1. Atrial Fibrillation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6. Non-Atrial Fibrillation
- 5.6.1. Non-Atrial Fibrillation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Pulsed Field Ablation Market: End Use Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Pulsed Field Ablation Market: End Use Movement Analysis
- 6.3. Pulsed Field Ablation Market by End Use Outlook (USD Million)
- 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.5. Inpatient Facilities
- 6.5.1. Inpatient Facilities Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6. Outpatient Facilities
- 6.6.1. Outpatient Facilities Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Pulsed Field Ablation Market: Regional Estimates & Trend Analysis
- 7.1. Regional Dashboard
- 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 7.3. North America
- 7.3.1. U.S.
- 7.3.1.1. Key country dynamics
- 7.3.1.2. Regulatory framework/ reimbursement structure
- 7.3.1.3. Competitive scenario
- 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 7.3.2. Canada
- 7.3.2.1. Key country dynamics
- 7.3.2.2. Regulatory framework/ reimbursement structure
- 7.3.2.3. Competitive scenario
- 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 7.3.3. Mexico
- 7.3.3.1. Key country dynamics
- 7.3.3.2. Regulatory framework/ reimbursement structure
- 7.3.3.3. Competitive scenario
- 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4. Europe
- 7.4.1. UK
- 7.4.1.1. Key country dynamics
- 7.4.1.2. Regulatory framework/ reimbursement structure
- 7.4.1.3. Competitive scenario
- 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.2. Germany
- 7.4.2.1. Key country dynamics
- 7.4.2.2. Regulatory framework/ reimbursement structure
- 7.4.2.3. Competitive scenario
- 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.3. France
- 7.4.3.1. Key country dynamics
- 7.4.3.2. Regulatory framework/ reimbursement structure
- 7.4.3.3. Competitive scenario
- 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.4. Italy
- 7.4.4.1. Key country dynamics
- 7.4.4.2. Regulatory framework/ reimbursement structure
- 7.4.4.3. Competitive scenario
- 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.5. Spain
- 7.4.5.1. Key country dynamics
- 7.4.5.2. Regulatory framework/ reimbursement structure
- 7.4.5.3. Competitive scenario
- 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.6. Norway
- 7.4.6.1. Key country dynamics
- 7.4.6.2. Regulatory framework/ reimbursement structure
- 7.4.6.3. Competitive scenario
- 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.7. Sweden
- 7.4.7.1. Key country dynamics
- 7.4.7.2. Regulatory framework/ reimbursement structure
- 7.4.7.3. Competitive scenario
- 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.8. Denmark
- 7.4.8.1. Key country dynamics
- 7.4.8.2. Regulatory framework/ reimbursement structure
- 7.4.8.3. Competitive scenario
- 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5. Asia Pacific
- 7.5.1. Japan
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Regulatory framework/ reimbursement structure
- 7.5.1.3. Competitive scenario
- 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.2. China
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Regulatory framework/ reimbursement structure
- 7.5.2.3. Competitive scenario
- 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.3. India
- 7.5.3.1. Key country dynamics
- 7.5.3.2. Regulatory framework/ reimbursement structure
- 7.5.3.3. Competitive scenario
- 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.4. Australia
- 7.5.4.1. Key country dynamics
- 7.5.4.2. Regulatory framework/ reimbursement structure
- 7.5.4.3. Competitive scenario
- 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.5. South Korea
- 7.5.5.1. Key country dynamics
- 7.5.5.2. Regulatory framework/ reimbursement structure
- 7.5.5.3. Competitive scenario
- 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.6. Thailand
- 7.5.6.1. Key country dynamics
- 7.5.6.2. Regulatory framework/ reimbursement structure
- 7.5.6.3. Competitive scenario
- 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6. Latin America
- 7.6.1. Brazil
- 7.6.1.1. Key country dynamics
- 7.6.1.2. Regulatory framework/ reimbursement structure
- 7.6.1.3. Competitive scenario
- 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.2. Argentina
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Regulatory framework/ reimbursement structure
- 7.6.2.3. Competitive scenario
- 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7. MEA
- 7.7.1. South Africa
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Regulatory framework/ reimbursement structure
- 7.7.1.3. Competitive scenario
- 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.2. Saudi Arabia
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Regulatory framework/ reimbursement structure
- 7.7.2.3. Competitive scenario
- 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.3. UAE
- 7.7.3.1. Key country dynamics
- 7.7.3.2. Regulatory framework/ reimbursement structure
- 7.7.3.3. Competitive scenario
- 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.4. Kuwait
- 7.7.4.1. Key country dynamics
- 7.7.4.2. Regulatory framework/ reimbursement structure
- 7.7.4.3. Competitive scenario
- 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Market Participant Categorization
- 8.2. Key Company Profiles
- 8.2.1. Boston Scientific Corporation
- 8.2.1.1. Company overview
- 8.2.1.2. Financial performance
- 8.2.1.3. Product benchmarking
- 8.2.1.4. Strategic initiatives
- 8.2.2. Abbott
- 8.2.2.1. Company overview
- 8.2.2.2. Financial performance
- 8.2.2.3. Product benchmarking
- 8.2.2.4. Strategic initiatives
- 8.2.3. Medtronic
- 8.2.3.1. Company overview
- 8.2.3.2. Financial performance
- 8.2.3.3. Product benchmarking
- 8.2.3.4. Strategic initiatives
- 8.2.4. Biosense Webster, Inc. (Johnson & Johnson Services, Inc
- 8.2.4.1. Company overview
- 8.2.4.2. Financial performance
- 8.2.4.3. Product benchmarking
- 8.2.4.4. Strategic initiatives
- 8.2.5. Pulse Biosciences, Inc
- 8.2.5.1. Company overview
- 8.2.5.2. Financial performance
- 8.2.5.3. Product benchmarking
- 8.2.5.4. Strategic initiatives
- 8.2.6. Kardium
- 8.2.6.1. Company overview
- 8.2.6.2. Financial performance
- 8.2.6.3. Product benchmarking
- 8.2.6.4. Strategic initiatives
- 8.2.7. Jia Jing Electronic Co., Ltd.
- 8.2.7.1. Company overview
- 8.2.7.2. Financial performance
- 8.2.7.3. Product benchmarking
- 8.2.7.4. Strategic initiatives